ISRCTN13265717CompletedPhase 1
Phase 1 trial: Labcorp code 8501022
Albireo (Sweden)0 sites76 target enrollmentStarted: March 23, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 76
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Exclusion Criteria
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Investigators
Similar Trials
Completed
Phase 1
Phase I trial: Labcorp Drug Development Study: 8479217The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN14340698Bergenbio ASA6
Completed
Phase 1
Phase I trial: Fortrea code: 8476207Healthy volunteersISRCTN88307799Vifor (International) Inc.8
Active, not recruiting
Phase 1
Phase I trial: PXL 272092ISRCTN45338135Hansa Biopharma (Sweden)8
Completed
Unknown
Phase 1 trial: CA38951Healthy volunteersISRCTN46343886Millicent Pharma Limited36
Active, not recruiting
Phase 1
Phase 1 trial, HMR code: 21-004The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.Not SpecifiedISRCTN12926361Gedeon Richter Plc104